Moreover, these findings underscore the urgent need to re-assess the “weak” estrogenic effects of parabens, particularly at environmentally achievable doses, in the presence of other factors that crosstalk and act in concert with ER signaling pathways to modulate breast cancer cell growth and development. The gene discussed is ESR1; the disease is breast carcinoma.